dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Morgensztern, Daniel |
dc.contributor.author | Trigo, José Manuel |
dc.contributor.author | Moreno, Victor |
dc.contributor.author | Curigliano, Giuseppe |
dc.contributor.author | Rutkowski, Piotr |
dc.date.accessioned | 2022-08-10T06:25:51Z |
dc.date.available | 2022-08-10T06:25:51Z |
dc.date.issued | 2022-04 |
dc.identifier.citation | Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, et al. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol. 2022 Apr;89:499–514. |
dc.identifier.issn | 1432-0843 |
dc.identifier.uri | https://hdl.handle.net/11351/7973 |
dc.description | Melanoma; Eficàcia de l'inhibidor de l'anticòs monoclonal PD-1; Farmacocinètica/farmacodinàmica |
dc.description.sponsorship | This study was funded by Janssen Research & Development. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Cancer Chemotherapy and Pharmacology;89 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Anticossos monoclonals - Ús terapèutic - Eficàcia |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.title | First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s00280-022-04414-6 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://doi.org/10.1007/s00280-022-04414-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Felip E] Unitat de Càncer Toràcic, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Moreno V] Phase 1 Trials Unit, START MADRID-FJD, Hospital Fundación Jiménez Díaz Medical Oncology Division, Madrid, Spain. [Morgensztern D] Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA. [Curigliano G] Division of Early Drug Development, European Institute of Oncology, IRCCS and University of Milano, Milan, Italy. [Rutkowski P] Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. [Trigo JM] Department of Medical Oncology, Hospital Universitario Virgen de La Victoria y Regional, Málaga, Spain |
dc.identifier.pmid | 35298698 |
dc.identifier.wos | 000770203700002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |